<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778865</url>
  </required_header>
  <id_info>
    <org_study_id>004/2020</org_study_id>
    <nct_id>NCT04778865</nct_id>
  </id_info>
  <brief_title>Effect of Treatment for Vitamin D Deficiency on Thyroid Function and Autoimmunity in Hashimoto's Thyroiditis.</brief_title>
  <official_title>Effect of Vitamin D Supplementation on Autoimmunity and Thyroid Function in Subjects With Hashimoto's Thyroiditis and Vitamin D Deficiency: Clinical Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Valparaiso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Valparaiso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of vitamin D supplementation on thyroid&#xD;
      autoimmunity, thyroid function, and other metabolic and clinical variables associated with&#xD;
      the thyroid axis in patients with Hashimoto's thyroiditis and vitamin D deficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will randomly receive the experimental condition or the active comparator for 3 months. After 3 months of washout, the groups will be crossed to receive the opposite treatment.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline antithyroid antibodies at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Anti-thyroid peroxidase and anti-thyroglobulin antibodies (UI/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Thyroid stimulating hormone at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Serum Thyroid stimulating hormone (TSH) (uIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Free thyroxine at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Serum Free thyroxine (FT4) (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Total triiodothyronine at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Serum Total triiodothyronine (T3) (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Lipid profile at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Lipid profile: It includes total cholesterol (mg/dl), high-density lipoprotein (HDL) (mg/dl), low-density lipoprotein (LDL) (mg/dl), very low-density lipoprotein (VLDL) (mg/dl), and triglycerides (mg/dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline glycemia at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Fasting glycemia (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ThyPro-39 at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Questionnaire ThyPro-39 (Quality of Life Questionnaire for Patients with Thyroid Disease): ThyPRO-39 measures the severity of symptoms and overall health-related quality of life of patients with thyroid disease, self-reported during the previous 4 weeks through a questionnaire. Each item on the questionnaire is rated by a five-point Likert scale (not at all, a little, somewhat, quite a bit, very much/completely). ThyPRO-39 is made up of 39 items in13 scales: goiter symptoms; hyperthyroid symptoms; hypothyroid symptoms; eye symptoms; tiredness; cognitive complaints; anxiety; depressivity; emotional susceptibility; impaired social life; impaired daily life; cosmetic complaints/appearance; and overall quality of life (QoL)-impact scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline SF-36 at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Questionnaire SF-36: The Short Form-36 Health Survey (SF-36) is a generic health-related quality of life (HRQL) questionnaires. The SF-36 Health Questionnaire is composed of 36 questions that assess health status through alternatives in items such as: Physical function, Physical role, Body pain, General health, Vitality, Social function, Emotional role and Mental health. Additionally, it includes an item on the change in general health status compared to the previous year.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline 25(OH)D at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>25(OH)D (ng/mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Parathormone at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>Parathormone (pg/mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline calcium at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>serum calcium (mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline phosphorus at 3 months</measure>
    <time_frame>Basal and final (after 3 months)</time_frame>
    <description>phosphorus (mg/dL)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hashimoto Disease</condition>
  <condition>Treatment Levothyroxine</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D-correction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D-RDA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D-correction</intervention_name>
    <description>Capsule with 50.000 UI cholecalciferol</description>
    <arm_group_label>Vitamin D-correction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D-RDA</intervention_name>
    <description>Capsule with 4.2000 UI cholecalciferol</description>
    <arm_group_label>Vitamin D-RDA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women between 18-45 years old (pre-menopausal stage)&#xD;
&#xD;
          -  men between 18-60 years old&#xD;
&#xD;
          -  BMI between 18.5-34.9 kg/ m2&#xD;
&#xD;
          -  medical diagnosis of Hashimoto's thyroiditis&#xD;
&#xD;
          -  treatment with levothyroxine (LT4) with stable dose (from four months from the start&#xD;
             of the intervention)&#xD;
&#xD;
          -  positive antithyroid antibody (peroxidase and/or thyroglobulin)&#xD;
&#xD;
          -  serum 25 (OH) D levels &lt;20 ng / ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  radioiodine, thyroidectomy, antithyroid treatment&#xD;
&#xD;
          -  disease, condition or drug treatment that alters the immune system or&#xD;
             hypothalamic-pituitary-thyroid axis or vitamin D metabolism.&#xD;
&#xD;
          -  disorder of kidney, liver, or bone-metabolic function&#xD;
&#xD;
          -  Graves disease, toxic nodular goiter, postpartum thyroiditis, coronary heart disease,&#xD;
             epilepsy, cancer, Turner or Down syndrome, primary hyperparathyroidism&#xD;
&#xD;
          -  vitamin D, calcium, complex B, omega-3 supplements&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  type 2 diabetes or dyslipidemia with drug treatment at unstable doses&#xD;
&#xD;
          -  intense physical activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabella A Vicu√±a, Master</last_name>
    <phone>56-976614192</phone>
    <email>isabella.vicuna@uv.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia A Vega, Master</last_name>
    <phone>5632-2508440</phone>
    <email>claudia.vega@uv.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Escuela de Nutrici√≥n. Facultad de Farmacia. Universidad de Valpara√≠so.</name>
      <address>
        <city>Valpara√≠so</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella A Vicu√±a, Master</last_name>
      <phone>56-976614192</phone>
      <email>isabella.vicuna@uv.cl</email>
    </contact>
    <contact_backup>
      <last_name>Claudia A Vega, Master</last_name>
      <phone>5632-2508440</phone>
      <email>claudia.vega@uv.cl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Valparaiso</investigator_affiliation>
    <investigator_full_name>Claudia Vega Soto</investigator_full_name>
    <investigator_title>Nutritionist</investigator_title>
  </responsible_party>
  <keyword>Hashimoto Disease</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Antithyroid antibodies</keyword>
  <keyword>Thyroid stimulating hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

